| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NBIX | Common Stock | Options Exercise | $775K | +21.5K | +114% | $35.99 | 40.4K | Aug 12, 2022 | Direct | |
| transaction | NBIX | Common Stock | Sale | -$2.28M | -21.5K | -53.27% | $105.95 | 18.9K | Aug 12, 2022 | Direct | F1, F2, F3 |
| transaction | NBIX | Common Stock | Options Exercise | $124K | +3.46K | +18.29% | $35.99 | 22.3K | Aug 15, 2022 | Direct | |
| transaction | NBIX | Common Stock | Options Exercise | $145K | +3.36K | +15.04% | $43.24 | 25.7K | Aug 15, 2022 | Direct | |
| transaction | NBIX | Common Stock | Options Exercise | $100K | +1.23K | +4.77% | $81.49 | 26.9K | Aug 15, 2022 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NBIX | Non-Qualified Stock Option | Options Exercise | -$775K | -21.5K | -100% | $35.99 | 0 | Aug 12, 2022 | Common Stock | 21.5K | $35.99 | Direct | F4 |
| transaction | NBIX | Incentive Stock Option | Options Exercise | -$124K | -3.46K | -100% | $35.99 | 0 | Aug 15, 2022 | Common Stock | 3.46K | $35.99 | Direct | F4 |
| transaction | NBIX | Incentive Stock Option | Options Exercise | -$145K | -3.36K | -100% | $43.24 | 0 | Aug 15, 2022 | Common Stock | 3.36K | $43.24 | Direct | F5 |
| transaction | NBIX | Incentive Stock Option | Options Exercise | -$100K | -1.23K | -100% | $81.49 | 0 | Aug 15, 2022 | Common Stock | 1.23K | $81.49 | Direct | F6 |
| Id | Content |
|---|---|
| F1 | The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. |
| F2 | Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.28 to $106.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F3 | Includes an aggregate of 157 shares purchased on February 28, 2022 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |
| F4 | Option granted February 05, 2016 and vested monthly over four years. |
| F5 | Option granted February 06, 2017 and vested monthly over four years |
| F6 | Option granted February 05, 2018 and vested monthly over four years |